Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Philip McCarthy: COSTEM highlights

Philip McCarthy • 26 Oct 2019
COSTEM 2019
General CAR-T Cyclophosphamide

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses his highlights from the COSTEM 2019 meeting, specifically mentioning the use of ATG, the Chinese CAR-T experience and post-transplant cyclophosphamide. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Philip McCarthy

4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals